BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34320515)

  • 41. A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer.
    Barni S; Ghidini A; Coinu A; Borgonovo K; Petrelli F
    Anticancer Drugs; 2014 Nov; 25(10):1122-8. PubMed ID: 24869761
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of surgery and adjuvant therapy in older patients with colorectal cancer: a STROBE-compliant article.
    Yang L; Ma Q; Yu YY; Wang C; Meng WJ; Adell G; Albertsson M; Arbman G; Jarlsfelt I; Peng ZH; Li Y; Zhou ZG; Sun XF
    Medicine (Baltimore); 2014 Dec; 93(28):e266. PubMed ID: 25526455
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis.
    Huang X; Gao P; Song Y; Sun J; Chen X; Zhao J; Liu J; Xu H; Wang Z
    BMC Cancer; 2014 Dec; 14():976. PubMed ID: 25519477
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study.
    Olén O; Erichsen R; Sachs MC; Pedersen L; Halfvarson J; Askling J; Ekbom A; Sørensen HT; Ludvigsson JF
    Lancet; 2020 Jan; 395(10218):123-131. PubMed ID: 31929014
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of renin-angiotensin system antagonists in the prevention of bevacizumab- and sunitinib-mediated cardiac dysfunction.
    Mozolevska V; Schwartz A; Cheung D; Goyal V; Shaikh B; Dingman B; Kim E; Mittal I; Asselin CY; Edel A; Ravandi A; Thliveris J; Singal PK; Czaykowski P; Jassal DS
    Am J Physiol Heart Circ Physiol; 2019 Mar; 316(3):H446-H458. PubMed ID: 30499710
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
    Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
    BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Insurance Coverage for CT Colonography Screening: Impact on Overall Colorectal Cancer Screening Rates.
    Smith MA; Weiss JM; Potvien A; Schumacher JR; Gangnon RE; Kim DH; Weeth-Feinstein LA; Pickhardt PJ
    Radiology; 2017 Sep; 284(3):717-724. PubMed ID: 28696184
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Trends in the prevalence of malignancy among patients admitted with acute heart failure and associated outcomes: a nationwide population-based study.
    Ram P; Tiu A; Lo KB; Parikh K; Shah M
    Heart Fail Rev; 2019 Nov; 24(6):989-995. PubMed ID: 31175492
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
    Song A; Eo W; Lee S
    World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of Arterial Hypertension on Doxorubicin-Based Chemotherapy-Induced Subclinical Cardiac Damage in Breast Cancer Patients.
    Vaitiekus D; Muckiene G; Vaitiekiene A; Maciuliene D; Vaiciuliene D; Ambrazeviciute G; Sereikaite L; Verikas D; Jurkevicius R; Juozaityte E
    Cardiovasc Toxicol; 2020 Jun; 20(3):321-327. PubMed ID: 31782105
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The impact of diabetes process and outcome quality measures on overall survival in patients with co-morbid colorectal cancer.
    Chiao EY; Nambi PV; Naik AD
    J Cancer Surviv; 2010 Dec; 4(4):381-7. PubMed ID: 20721633
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Trends in chemotherapy utilization for colorectal cancer.
    Renouf D; Kennecke H; Gill S
    Clin Colorectal Cancer; 2008 Nov; 7(6):386-9. PubMed ID: 19036691
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Insulin enhances and metformin reduces risk of colorectal carcinoma in type-2 diabetes.
    Chen CH; Lin CL; Hsu CY; Kao CH
    QJM; 2020 Mar; 113(3):194-200. PubMed ID: 31593243
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of age and comorbidity on prognosis and application of adjuvant chemotherapy in elderly Japanese patients with colorectal cancer: A retrospective multicentre study.
    Yamano T; Yamauchi S; Kimura K; Babaya A; Hamanaka M; Kobayashi M; Fukumoto M; Tsukamoto K; Noda M; Tomita N; Sugihara K;
    Eur J Cancer; 2017 Aug; 81():90-101. PubMed ID: 28622612
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk factors for developing cardiac toxicities in cancer patients treated with panitumumab combination therapy.
    Qi WX; Zhao S; Chen J
    Future Oncol; 2020 Jul; 16(19):1359-1370. PubMed ID: 32422068
    [No Abstract]   [Full Text] [Related]  

  • 56. Increased Risk of Colorectal Cancer in Individuals With a History of Serrated Polyps.
    Li D; Liu L; Fevrier HB; Alexeeff SE; Doherty AR; Raju M; Amsden LB; Lee JK; Levin TR; Corley DA; Herrinton LJ
    Gastroenterology; 2020 Aug; 159(2):502-511.e2. PubMed ID: 32277950
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer.
    Polk A; Shahmarvand N; Vistisen K; Vaage-Nilsen M; Larsen FO; Schou M; Nielsen DL
    BMJ Open; 2016 Oct; 6(10):e012798. PubMed ID: 27798021
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fluoropyrimidine‑induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT).
    Lombardi P; Aimar G; Peraldo-Neia C; Bonzano A; Depetris I; Fenocchio E; Filippi R; Quarà V; Milanesio M; Cavalloni G; Gammaitoni L; Basiricò M; Cagnazzo C; Ostano P; Chiorino G; Aglietta M; Leone F
    Oncol Rep; 2023 Feb; 49(2):. PubMed ID: 36562382
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
    Upshaw JN; Ruthazer R; Miller KD; Parsons SK; Erban JK; O'Neill AM; Demissei B; Sledge G; Wagner L; Ky B; Kent DM
    Clin Breast Cancer; 2019 Aug; 19(4):259-267.e1. PubMed ID: 31175052
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nuclear medicine in the assessment and prevention of cancer therapy-related cardiotoxicity: prospects and proposal of use by the European Association of Nuclear Medicine (EANM).
    Totzeck M; Aide N; Bauersachs J; Bucerius J; Georgoulias P; Herrmann K; Hyafil F; Kunikowska J; Lubberink M; Nappi C; Rassaf T; Saraste A; Sciagra R; Slart RHJA; Verberne H; Rischpler C
    Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):792-812. PubMed ID: 36334105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.